Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy

Vemuru, Sudheer; Huang, Jin; Colborn, Kathryn; Yoon, YooJin; Huynh, Victoria; Leonard, Laura D.; Ahrendt, Gretchen; Christian, Nicole; Afghahi, Anosheh; McLemore, Lauren; Sams, Sharon B.; Tevis, Sarah E.

doi:10.1007/s10549-023-06978-0

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vemuru et al found that HR+ tumors were more likely than HR− tumors to have a receptor conversion (37% vs 11%; p < 0.01). Furthermore, patients with stage 0-II disease after NAC were more likely to have receptor conversions than those with stage III-IV disease (35% vs 13%; p = 0.02) 20 . Previous studies on the change in HR and HER-2 status after NAC have presented conflicting results.…”

Section: Discussionmentioning

confidence: 95%

Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?

Uzun,

Atag,

Caliskan Yildirim

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Biomarkers such as hormone receptors (HR) and human epidermal growth factor receptor2 (HER2) may change after neoadjuvant chemotherapy (NAC) in breast cancer patients. The aim of this study was to investigate the rates of receptor change after NAC and to evaluate the prognostic impact of change. Patients with breast cancer who received NAC were included in the study. Changes in pathological findings (ER, PR, HER-2, Ki-67, grade) before and after NAC were examined. In addition, the effect of receptor exchange on prognosis was evaluated. Kaplan Meier analysis was used for survival analyses. Study was approved by Ethics Board of Tepecik Training and Research Hospital (Decision number 2021/10-02). We confirm that all methods were performed in accordance with relevant named guidelines and regulations. The study included 203 female patients. When pathological findings before and after NAC were compared, significant regression was found in grade and Ki-67 values (p = 0.003, p < 0.001). ER change rate was 11.8%, PR change rate was 24.6% and HER-2 change rate was 12.5%. No significant correlation was found between ER, PR and HER-2 changes and prognosis. The pathological T stage after NAC being 1 or 2, no lymph nodes detected, and the tumor grade being 1 or 2 were independent variables related to survival (p: 0.002, p: 0.014, p < 0.001). In patients with breast cancer, it would be appropriate to re-evaluate the HER-2 and HR status of the surgical specimen following NAC, especially in initially negative patients. The correlation of receptor discordance with prognosis is not clear and more extensive studies are needed.

show abstract

Section: Discussionmentioning

confidence: 95%

Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?

Uzun,

Atag,

Caliskan Yildirim

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Механизмы изменения биотипа опухоли. РМЖ, как и любая другая опухоль, являясь гетерогенной по клеточному составу, характеризуется различными по скорости роста кариотипом, иммуногенностью, наличием или отсутствием РЭ / РП, синтезом опухолеассоциированных белков, а следовательно, различными по чувствительности к лекарственной и лучевой терапии субпопуляциями клеток [14]. Опухоль, взаимодействуя с окружающими тканями и условиями среды, в том числе испытывая влияние гипоксии, лекарственного и гормонального воздействия, способна претерпевать генетические изменения [15].…”

Section: Introductionunclassified

Changing the phenotype of breast cancer in the process treatment: literature review

Shvedsky,

Tamrazov,

Shevlyukova

et al. 2024

Onkol. koloproktol.

View full text Add to dashboard Cite

A review of the literature concerning the issue of changing the phenotype of breast cancer during treatment is presented. In the Russian Federation, breast cancer (breast cancer) occupies a leading position in the structure of morbidity and mortality of female oncological diseases. Many retrospective studies have reported changes in the expression of bio-markers in surgical samples after neoadjuvant therapy. The study of changes in biological subtypes can change approaches to therapy and contribute to an increase in survival rates in such patients. Based on these data, we can talk about the need for repeated assessments of the tumor biotype during treatment, which contributes to an optimal and personalized approach to breast cancer therapy.

show abstract

Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy

Cited by 2 publications

References 33 publications

Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?

Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?

Changing the phenotype of breast cancer in the process treatment: literature review

Contact Info

Product

Resources

About